INSTIL BIO INC
TILNASDAQTrading Snapshot
- Day Range
- $7.08 β $7.18
- 52-Week Range
- $5.67 β $21.98
- Volume
- $2.52B
- Avg Volume
- $2.74B
- Shares Outstanding
- 6.8M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- -1.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-4.46
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.9%
Why Investors Own TIL
- βHigh-growth profile β revenue up +43.8% YoY with expanding US Equity exposure.
- βHealthy economics β 62% gross margin and 15% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INSTIL BIO INC
TIL
StockOtter Β· stockotter.spaceAbout INSTIL BIO INC
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
Iovance Biotherapeutics NASDAQ: IOVA said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (βInstilβ) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
Obsidian Therapeutics, Inc. (Γ’ΒΒObsidianΓ’ΒΒ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)
Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip was attributed to one